IMV
$2.799876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$2.79
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.04 (-1.41%) As of 1:22 PM EST today
-$0.04 (-1.41%) Today
Why Robinhood?
You can buy or sell IMV and other stocks, options, ETFs, and crypto commission-free!
About IMV
IMV Inc. Common Shares, also called IMV, is a clinical-stage biopharmaceutical company pioneering a new class of immunotherapy in Oncology. Read More Its proprietary drug delivery platform (DPX) enables the programming of immune cells in vivo. The firm's candidate, DPX-Survivac, is a T cell-activating immunotherapy combining DPX with a specific tumor target: Survivin. DPX-Survivac is in clinical evaluation as a monotherapy in advanced ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications. The company was founded by Warwick Kimmins and Brian E. Lowe on March 28, 2000 and is headquartered in Dartmouth, Canada.
CEO
Employees
—
Headquarters
Dartmouth, Nova Scotia
Founded
2000
Market Cap
143.23M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
13.91K
High Today
$2.98
Low Today
$2.71
Open Price
$2.98
Volume
9.28K
52 Week High
$6.02
52 Week Low
$2.11
Collections
IMV News
Financial PostDec 8
Updated Clinical Data from Phase 2 SPiReL Study Evaluating DPX-Survivac as a Combination Therapy in r/r DLBCL Presented at 61st American Society of Hematology Annual Meeting
7/9 (77.8%) evaluable subjects exhibited clinical benefit, including three complete responses and two partial responses Reproducible survivin-specific T cell rAnalyst Ratings
88%
of 8 ratings
Buy
88%
Hold
13%
Sell
0%
IMV Earnings
-$0.13
-$0.11
-$0.10
-$0.08
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
—
Actual
—